Journal article
Economic benefits of pioglitazone for treating patients with Type 2 diabetes
Abstract
Diabetes remains a significant economic burden to national healthcare systems. The traditional oral agents used to treat Type 2 diabetes do not address the underlying insulin resistance responsible for the development of diabetes. Newer medications, such as the thiazolidinediones, have been shown to reverse some of the metabolic processes believed to be responsible for the development of insulin resistance and ultimately, Type 2 diabetes. A …
Authors
Grossman LD; Longo CJ
Journal
Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 4, No. 2, pp. 135–142
Publisher
Taylor & Francis
Publication Date
April 2004
DOI
10.1586/14737167.4.2.135
ISSN
1473-7167